MX2019002578A - Métodos de detección de la expresión del ligando 1 de muerte programada por célula y usos de los mismos. - Google Patents

Métodos de detección de la expresión del ligando 1 de muerte programada por célula y usos de los mismos.

Info

Publication number
MX2019002578A
MX2019002578A MX2019002578A MX2019002578A MX2019002578A MX 2019002578 A MX2019002578 A MX 2019002578A MX 2019002578 A MX2019002578 A MX 2019002578A MX 2019002578 A MX2019002578 A MX 2019002578A MX 2019002578 A MX2019002578 A MX 2019002578A
Authority
MX
Mexico
Prior art keywords
expression
methods
per cell
detecting
cell
Prior art date
Application number
MX2019002578A
Other languages
English (en)
Inventor
k patterson Bruce
Noel Chargin Amanda
Shults Keith
Original Assignee
Incelldx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incelldx Inc filed Critical Incelldx Inc
Publication of MX2019002578A publication Critical patent/MX2019002578A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1486—Counting the particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proporcionan metodos para la deteccion de la expresion del ligando 1 de muerte programada (PD-L1) por celula de celulas de neoplasia; los aspectos de los metodos incluyen examinar citometricamente una suspension de celulas marcadas para cuantificar la expresion de PD-L1 por celula para detectar si una celula neoplasica que expresa PD-L1 arriba de un umbral predeterminado esta presente en la muestra de neoplasia; ademas, tambien se proporcionan kits que se usan en la practica de los metodos presentes.
MX2019002578A 2016-09-06 2017-09-06 Métodos de detección de la expresión del ligando 1 de muerte programada por célula y usos de los mismos. MX2019002578A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662384037P 2016-09-06 2016-09-06
PCT/US2017/050322 WO2018048936A1 (en) 2016-09-06 2017-09-06 Methods of detecting per cell pd-l1 expression and uses thereof

Publications (1)

Publication Number Publication Date
MX2019002578A true MX2019002578A (es) 2019-09-18

Family

ID=61561676

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002578A MX2019002578A (es) 2016-09-06 2017-09-06 Métodos de detección de la expresión del ligando 1 de muerte programada por célula y usos de los mismos.

Country Status (11)

Country Link
US (1) US10782298B2 (es)
EP (1) EP3510378A4 (es)
JP (2) JP2019535001A (es)
CN (2) CN109906367A (es)
BR (1) BR112019004470A2 (es)
CA (1) CA3036278A1 (es)
CR (1) CR20190172A (es)
IL (1) IL265175A (es)
MX (1) MX2019002578A (es)
SG (1) SG11201901991QA (es)
WO (2) WO2018048936A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11726089B2 (en) 2016-09-06 2023-08-15 Incelldx, Inc. Methods of assaying neoplastic and neoplasia-related cells and uses thereof
SG11201901991QA (en) 2016-09-06 2019-04-29 Incelldx Inc Methods of detecting per cell pd-l1 expression and uses thereof
JP7259019B2 (ja) * 2018-09-20 2023-04-17 ヴェンタナ メディカル システムズ， インク． フローサイトメトリデータを分析するためのサイズに基づくゲーティング
CN113330310A (zh) * 2018-11-09 2021-08-31 皮埃里亚生物科学有限责任公司 用于测定肿瘤微环境组成的方法和组合物
US20220107320A1 (en) * 2019-02-15 2022-04-07 Incelldx, Inc. Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
CN110142068B (zh) * 2019-06-12 2024-02-02 杭州华得森生物技术有限公司 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法
CN111735955A (zh) * 2020-04-20 2020-10-02 山东省肿瘤防治研究院（山东省肿瘤医院） 一种肝细胞癌患者外周血循环肿瘤细胞上pd-l1表达的免疫荧光检测方法
WO2022190099A1 (en) * 2021-03-10 2022-09-15 B.G. Negev Technologies & Applications Ltd., At Ben-Gurion University Reporter cells expressing chimeric polypeptides for use in determining presence and or activity of immune checkpoint molecules
CN113358872B (zh) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于评估肿瘤免疫治疗疗效的标志物组及系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1588162B1 (en) * 2003-01-03 2008-09-17 Aurelium Biopharma Inc. Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
MX2007004176A (es) * 2004-10-06 2007-06-15 Mayo Foundation B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
WO2007136026A1 (ja) * 2006-05-19 2007-11-29 Bml, Inc. 抗原タンパク質の定量方法及び定量用キット
SG11201407190TA (en) * 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20150071910A1 (en) 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2015034820A1 (en) * 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
SI3702373T1 (sl) 2013-09-13 2022-11-30 Beigene Switzerland Gmbh Protitelesa proti PD-1 in njihova uporaba kot terapevtiki in diagnostiki
EP3060919A4 (en) * 2013-10-25 2018-02-14 Nodality, Inc. Methods and compositions for immunomodulation
JP6355154B2 (ja) * 2014-04-03 2018-07-11 公益財団法人ヒューマンサイエンス振興財団 診断補助方法
PE20171067A1 (es) * 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
US20170242016A1 (en) 2014-10-15 2017-08-24 Epic Sciences, Inc. Circulating tumor cell diagnostics for therapy targeting pd-l1
WO2017040620A1 (en) * 2015-09-01 2017-03-09 Academia Sinica Antagonistic pdl1 aptamers and their applications in cancer therapy
LT3368683T (lt) 2015-10-27 2020-04-10 Pharmassist Ltd Pd-l1 kiekybinio įvertinimo būdas
SG11201901991QA (en) 2016-09-06 2019-04-29 Incelldx Inc Methods of detecting per cell pd-l1 expression and uses thereof

Also Published As

Publication number Publication date
JP2022133307A (ja) 2022-09-13
WO2018048936A1 (en) 2018-03-15
SG11201901991QA (en) 2019-04-29
IL265175A (en) 2019-05-30
CA3036278A1 (en) 2018-03-15
EP3510378A1 (en) 2019-07-17
CN112088309A (zh) 2020-12-15
BR112019004470A2 (pt) 2019-09-03
JP2019535001A (ja) 2019-12-05
CR20190172A (es) 2019-06-13
WO2019136082A1 (en) 2019-07-11
CN109906367A (zh) 2019-06-18
US10782298B2 (en) 2020-09-22
US20180136214A1 (en) 2018-05-17
EP3510378A4 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
MX2019002578A (es) Métodos de detección de la expresión del ligando 1 de muerte programada por célula y usos de los mismos.
MX2017015011A (es) Ensayo a base de celulas para detectar homodimeros anti-cd3.
NZ711723A (en) Microfluidic devices and methods for use thereof in multicellular assays of secretion
EP4306659A3 (en) A method and kit for determining the tissue or cell origin of dna
GB2532672A (en) Methods and systems for analysis of organ transplantation
AU2014340098A8 (en) Micro-fluidic devices for assaying biological activity
GB2531881A (en) Method of isolating circulating tumor cells
MX2017005750A (es) Ensayos para detectar subgrupos inmunes de células t y sus métodos de uso.
MX2020004617A (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
WO2015148980A3 (en) Methods for detecting and reversing beta cell de-differentiation and uses thereof
WO2014205184A3 (en) Classification system, methods and kit for classifying. predicting and treating breast cancer
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
MX2016002692A (es) Camara de muestreo con depurador que reacciona con sulfuro de hidrogeno.
MX2017014196A (es) Deteccion de factores de virulencia microbiana bucal.
MX2017006097A (es) Libs para caracterizacion de fluido de materiales porosos.
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
PH12015501778A1 (en) Markers associated with wnt inhibitors
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer
WO2015003160A3 (en) Hepatocytes in co-culture and uses thereof
CL2024000180A1 (es) Composiciones y métodos para tratar la endometriosis.
JP2014501929A5 (es)
MX2015013993A (es) Procedimientos y series para su uso en los mismos.
IN2014DN08430A (es)
MX2022001898A (es) Metodos para el tratamiento de enfermedades asociadas a la senescencia.
SG11201811433TA (en) Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method